MARKET

CAPR

CAPR

Capricor Therapeutics Inc
NASDAQ
5.04
+0.22
+4.56%
After Hours: 5.13 +0.09 +1.79% 18:33 04/24 EDT
OPEN
5.26
PREV CLOSE
4.820
HIGH
5.65
LOW
5.00
VOLUME
919.73K
TURNOVER
0
52 WEEK HIGH
8.22
52 WEEK LOW
2.680
MARKET CAP
158.77M
P/E (TTM)
-6.0555
1D
5D
1M
3M
1Y
5Y
CAPRICOR THERAPEUTICS INC: GRANTED SUBSEQUENT TYPE-B CLINICAL MEETING WITH FDA IN Q2 TO CONTINUE TO DISCUSS PATHWAY TO BLA
Reuters · 18h ago
CAPRICOR THERAPEUTICS ANNOUNCES POSITIVE TYPE-B MEETING WITH FDA FOR CAP-1002 PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY
Reuters · 18h ago
CAPRICOR THERAPEUTICS: FDA FEEDBACK SUPPORTS REQUESTS FOR PRE-BLA MEETING,SUBSEQUENT ROLLING BLA SUBMISSION FOLLOWING UPCOMING Q2 TYPE-B FDA MEETING
Reuters · 18h ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 1d ago
Weekly Report: what happened at CAPR last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at CAPR last week (0408-0412)?
Weekly Report · 04/15 12:06
Weekly Report: what happened at CAPR last week (0401-0405)?
Weekly Report · 04/08 12:13
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
Healthcare Solid Biosciences gets FDA rare pediatric disease status for DMD therapy. SGT-003 for the treatment of Duchenne muscular dystrophy. The company expects the first patient in a Phase 1/2 study for the therapy to be dosed in Q2.
Seeking Alpha · 04/01 14:17
More
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Webull offers Capricor Therapeutics Inc stock information, including NASDAQ: CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.